Study Status
Concluded
DAIDS Number
10051
IND Number
BB 12268
Primary Protocol Team Members
Summary
P1059 was Phase I, open-label study among HIV-infected youth receiving treatment in the United States. The study was designed to determine the safety and tolerability of recombinant MVA and Fowlpox HIV-1 vaccines in HIV-1-infected young adults with good control of HIV replication (HIV RNA < 100 copies/mL for 6 months) on stable antiretroviral therapy.